Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics, Inc. (APRE)
:APRE
APRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $5.01
Previous CloseN/A
Volume2.88K
Average Volume (3M)35.88K
Market Cap
$8.74M
Enterprise Value-$5.52M
Total Cash (Recent Filing)$16.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Nov 06, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding5,825,261
10 Day Avg. Volume33,408
30 Day Avg. Volume35,882
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.63
Enterprise Value/Revenue-8.14
Enterprise Value/Gross Profit-6.74
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$10.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Development StrategyAprea's WEE1i and ATRi candidates have continued to make progress in early stage studies and management continues to execute on its development strategy.
Drug EfficacyThe strategy of continuous dosing has already demonstrated enhanced safety/tolerability profiles as well as early signals of efficacy.
Bears Say
Market ConditionsAPRE shares have pulled back significantly mainly from challenging macro market factors, particularly for microcap biotech.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics, Inc.’s price range in the past 12 months?
Aprea Therapeutics, Inc. lowest stock price was $1.41 and its highest was $5.01 in the past 12 months.
What is Aprea Therapeutics, Inc.’s market cap?
Aprea Therapeutics, Inc.’s market cap is $8.74M.
When is Aprea Therapeutics, Inc.’s upcoming earnings report date?
Aprea Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 47 days.
How were Aprea Therapeutics, Inc.’s earnings last quarter?
Aprea Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.181.
Is Aprea Therapeutics, Inc. overvalued?
According to Wall Street analysts Aprea Therapeutics, Inc.’s price is currently Undervalued.
Does Aprea Therapeutics, Inc. pay dividends?
Aprea Therapeutics, Inc. does not currently pay dividends.
What is Aprea Therapeutics, Inc.’s EPS estimate?
Aprea Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Aprea Therapeutics, Inc. have?
Aprea Therapeutics, Inc. has 5,825,261 shares outstanding.
What happened to Aprea Therapeutics, Inc.’s price movement after its last earnings report?
Aprea Therapeutics, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of Aprea Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APRE
Company Description
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$10.00
▲(566.67% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Carisma Therapeutics
―
Dogwood Therapeutics
―
Evaxion Biotech
―
Acurx Pharmaceuticals
―
Ownership Overview
11.83% Insiders
3.80% Mutual Funds
24.59% Other Institutional Investors
57.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---